Claire E. Gustafson

Claire E. Gustafson

Auto-generated profile, based on publicly available information

Claire E. Gustafson

Allen Institute for Immunology

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CGClaire E. Gustafson
Claire E. Gustafson
CKChulwoo Kim
Chulwoo Kim
CWCornelia M. Weyand
Cornelia M. Weyand
JGJörg J. Goronzy
Jörg J. Goronzy

29 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
QGQiuyu Gong
Qiuyu Gong
MSMehul Sharma
Mehul Sharma
MGMarla Glass
Marla Glass
EKEmma L. Kuan
Emma L. Kuan
ACAishwarya Chander
Aishwarya Chander
CGClaire E. Gustafson
Claire E. Gustafson
The generation and maintenance of immunity is a dynamic process that is dependent on age1,2,3. Here, to better understand its progression, we profiled peripheral immunity in more than 300 healthy adults (25 to 90 years of age) using single-cell RNA sequencing, proteomics and flow cytometry, following 96 adults longitudinally across 2 years with seasonal influenza vaccination. The resulting resource generated a single-cell RNA-sequencing dataset of more than 16 million peripheral blood mononuclear cells with 71 immune cell subsets from our Human Immune Health Atlas and enabled us to interrogate how immune cell composition and states shift with age, chronic viral infection and vaccination. From these data, we demonstrate robust, non-linear transcriptional reprogramming in T cell subsets with age that is not driven by systemic inflammation or chronic cytomegalovirus infection. This age-related reprogramming led to a functional T helper 2 (TH2) cell bias in memory T cells that is linked to dysregulated B cell responses against highly boosted antigens in influenza vaccines. Collectively, this study reveals unique features of the immune ageing process that occur prior to advanced age and provides novel targets for age-related immune modulation. We provide interactive tools for exploring this extensive human immune health resource at https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/.

1 January 2017 in Seminars in Hematology
Verified
Journal Article
Open access
RYRolando E. Yanes
Rolando E. Yanes
CGClaire E. Gustafson
Claire E. Gustafson
CWCornelia M. Weyand
Cornelia M. Weyand
JGJörg J. Goronzy
Jörg J. Goronzy
Immune aging is a multi-faceted process that manifests as reduced competence to fight infections and malignant cells, as well as diminished tissue repair, unprovoked inflammation, and increased autoreactivity. The aging adaptive immune system, with its high complexity in functional cell subpopulations and diversity of B- and T-cell receptors, has to cope with the challenge of maintaining homeostasis while responding to exogenous stimuli and compensating for reduced generative capacity. With thymic involution, naïve T cells begin to function as quasi-stem cells and maintain the compartment through peripheral homeostatic proliferation that shapes the T-cell repertoire through peripheral selection and the activation of differentiation pathways. Similarly, reduced generation of early B-cell progenitors alters the composition of the peripheral B-cell compartment with the emergence of a unique, auto-inflammatory B-cell subset, termed age-associated B cells (ABCs). These changes in T- and B-cell composition and function are core manifestations of immune aging.

1 July 2019 in Aging Cell
Verified
Journal Article
Open access
PDF file
BHBin Hu
Bin Hu
GLGuangjin Li
Guangjin Li
ZYZhongde Ye
Zhongde Ye
CGClaire E. Gustafson
Claire E. Gustafson
LTLu Tian
Lu Tian
JGJörg J. Goronzy
Jörg J. Goronzy
With reduced thymic activity, the population of naïve T cells in humans is maintained by homeostatic proliferation throughout adult life. In young adults, naïve CD4 T cells have enormous proliferative potential and plasticity to differentiate into different lineages. Here, we explored whether naïve CD4 T‐cell aging is associated with a partial loss of this unbiased multipotency. We find that naïve CD4 T cells from older individuals have developed a propensity to develop into TH9 cells. Two major mechanisms contribute to this predisposition. First, responsiveness to transforming growth factor β (TGFβ) stimulation is enhanced with age due to an upregulation of the TGFβR3 receptor that results in increased expression of the transcription factor PU.1. Secondly, aged naïve CD4 T cells display altered transcription factor profiles in response to T‐cell receptor stimulation, including enhanced expression of BATF and IRF4 and reduced expression of ID3 and BCL6. These transcription factors are involved in TH9 differentiation as well as IL9 transcription suggesting that the aging‐associated changes in the transcription factor profile favor TH9 commitment.

14 June 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
CGClaire E. Gustafson
Claire E. Gustafson
QQQian Qi
Qian Qi
JHJessica Hutter-Saunders
Jessica Hutter-Saunders
SGSheena Gupta
Sheena Gupta
RJRohit Jadhav
Rohit Jadhav
JGJörg J. Goronzy
Jörg J. Goronzy
Aging is associated with an increased susceptibility to infection and a failure to control latent viruses, that is thought to be driven, at least in part, by alterations in CD8 T cell function. The aging T cell repertoire is characterized by an accumulation of effector CD8 T cells, many of which express the negative regulatory receptor CD85j. To define the biological significance of CD85j expression on CD8 T cells and to address the question whether presence of CD85j in older individuals is beneficial or detrimental for immune function, we examined the specific attributes of CD8 T cells expressing CD85j as well as the functional role of CD85j in antigen-specific CD8 T cell responses during immune aging. Here, we show that CD85j is mainly expressed by terminally differentiated effector (TEMRAs) CD8 T cells, which increase with age, in CMV infection and in males. CD85j+ CMV-specific cells demonstrate clonal expansion. However, TCR diversity is similar between CD85j+ and CD85j- compartments, suggesting that CD85j does not directly impact the repertoire of antigen-specific cells. Further phenotypic and functional analyses revealed that CD85j identifies a specific subset of CMV-responsive CD8 T cells that co-express a marker of senescence (CD57) but retain poly-functional cytokine production and expression of cytotoxic mediators. Blocking CD85j binding enhanced proliferation of CMV-specific CD8 T cells upon antigen stimulation but did not alter polyfunctional cytokine production. Taken together, these data demonstrate that CD85j characterizes a population of “senescent”, but not exhausted antigen-specific effector CD8 T cells and indicates that CD85j is an important checkpoint regulator controlling expansion of virus-specific T cells during aging. Inhibition of CD85j activity may be a mechanism to promote stronger CD8 T cell effector responses during immune aging.

5 September 2018 in Clinical Science
Verified
Journal Article
Closed access
PDF file
CGClaire E. Gustafson
Claire E. Gustafson
CWCornelia M. Weyand
Cornelia M. Weyand
JGJörg J. Goronzy
Jörg J. Goronzy
By 2050, there will be over 1.6 billion adults aged 65 years and older, making age-related diseases and conditions a growing public health concern. One of the leading causes of death in the ageing population is pathogenic infections (e.g. influenza, Streptococcus pneumoniae). This age-dependent susceptibility to infection has been linked to a reduced ability of the ageing immune system to mount protective responses against infectious pathogens, as well as to vaccines against these pathogens. The primary immune response that promotes protection is the production of antibodies by B cells – a response that is directly mediated by T follicular helper (TFH) cells within germinal centers (GCs) in secondary lymphoid tissues. In this review, we will summarize the current knowledge on the development and functionality of TFH cells, the use of circulating TFH (cTFH) cells as vaccine biomarkers, and the influence of age on these processes. Moreover, we will discuss the strategies for overcoming TFH cell dysfunction to improve protective antibody responses in the ageing human population.